{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:01Z","timestamp":1786982761093,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T00:00:00Z","timestamp":1384560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40263-013-0124-4","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T07:29:10Z","timestamp":1384500550000},"page":"63-68","source":"Crossref","is-referenced-by-count":48,"title":["Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone"],"prefix":"10.1007","volume":"28","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,16]]},"reference":[{"key":"124_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","volume":"1147","author":"RK Chaturvedi","year":"2008","unstructured":"Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N\u00a0Y Acad Sci. 2008;1147:395\u2013412.","journal-title":"Ann N\u00a0Y Acad Sci."},{"key":"124_CR2","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1210\/en.2003-0163","volume":"144","author":"TL Horvath","year":"2003","unstructured":"Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M, et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson\u2019s disease. Endocrinology. 2003;144:2757\u201360.","journal-title":"Endocrinology."},{"key":"124_CR3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/exnr.1999.7049","volume":"157","author":"RT Matthews","year":"1999","unstructured":"Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142\u20139.","journal-title":"Exp Neurol."},{"key":"124_CR4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/bbrc.2001.5868","volume":"288","author":"S Harada","year":"2001","unstructured":"Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson\u2019s disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun. 2001;288:887\u201392.","journal-title":"Biochem Biophys Res Commun."},{"key":"124_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbabio.2011.10.012","volume":"1817","author":"V Giorgio","year":"2012","unstructured":"Giorgio V, Petronilli V, Ghelli A, Carelli V, Rugolo M, Lenaz G, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta. 2012;1817:363\u20139.","journal-title":"Biochim Biophys Acta."},{"key":"124_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1212115","volume":"369","author":"The Multiple-System Atrophy Research Collaboration","year":"2013","unstructured":"The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369:233\u201344.","journal-title":"N Engl J Med."},{"key":"124_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00023210-200923030-00003","volume":"23","author":"AY Tsou","year":"2009","unstructured":"Tsou AY, Friedman LS, Wilson RB, Lynch DR. Pharmacotherapy for Friedreich ataxia. CNS Drugs. 2009;23:213\u201323.","journal-title":"CNS Drugs."},{"key":"124_CR8","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http:\/\/www.cochrane-handbook.org ."},{"key":"124_CR9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000238518.34389.12","volume":"67","author":"A Bender","year":"2006","unstructured":"Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67:1262\u20134.","journal-title":"Neurology."},{"key":"124_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1545968306293449","volume":"21","author":"CJ Hass","year":"2007","unstructured":"Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21:107\u201315.","journal-title":"Neurorehabil Neural Repair."},{"key":"124_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(03)00185-X","volume":"341","author":"T M\u00fcller","year":"2003","unstructured":"M\u00fcller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson\u2019s disease. Neurosci Lett. 2003;341:201\u20134.","journal-title":"Neurosci Lett."},{"key":"124_CR12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"The NINDS NET-PD Investigators","year":"2006","unstructured":"The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664\u201371.","journal-title":"Neurology."},{"key":"124_CR13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"The NINDS NET-PD Investigators","year":"2007","unstructured":"The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20\u20138.","journal-title":"Neurology."},{"key":"124_CR14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541\u201350.","journal-title":"Arch Neurol."},{"key":"124_CR15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","volume":"25","author":"BJ Snow","year":"2010","unstructured":"Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O\u2019Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease. Mov Disord. 2010;25:1670\u20134.","journal-title":"Mov Disord."},{"key":"124_CR16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.64.7.nct60005","volume":"64","author":"A Storch","year":"2007","unstructured":"Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64:938\u201344.","journal-title":"Arch Neurol."},{"key":"124_CR17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","volume":"23","author":"M Stamelou","year":"2008","unstructured":"Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942\u20139.","journal-title":"Mov Disord."},{"key":"124_CR18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology. 2006;66:250\u20132.","journal-title":"Neurology."},{"key":"124_CR19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"The Huntington Study Group","year":"2001","unstructured":"The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology. 2001;57:397\u2013404.","journal-title":"Neurology."},{"key":"124_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","volume":"11","author":"NG Ranen","year":"1996","unstructured":"Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al. A controlled trial of idebenone in Huntington\u2019s disease. Mov Disord. 1996;11:549\u201354.","journal-title":"Mov Disord."},{"key":"124_CR21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","volume":"6","author":"NA Prospero Di","year":"2007","unstructured":"Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomized, placebo-controlled trial. Lancet Neurol. 2007;6:878\u201386.","journal-title":"Lancet Neurol."},{"key":"124_CR22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941\u20137.","journal-title":"Arch Neurol."},{"key":"124_CR23","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1212\/01.WNL.0000055872.50364.FC","volume":"60","author":"C Mariotti","year":"2003","unstructured":"Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676\u20139.","journal-title":"Neurology."},{"key":"124_CR24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-004-0216-x","volume":"112","author":"L Sch\u00f6ls","year":"2005","unstructured":"Sch\u00f6ls L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, et al. L-carnitine and creatine in Friedreich\u2019s ataxia: a randomized, placebo-controlled crossover trial. J Neural Transm. 2005;112:789\u201396.","journal-title":"J Neural Transm."},{"issue":"639\u2013645","key":"124_CR25","first-page":"e1","volume":"161","author":"SJ Lagedrost","year":"2011","unstructured":"Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, et al. Idebenone in Friedreich ataxia cardiomyopathy: results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(639\u2013645):e1.","journal-title":"Am Heart J."},{"key":"124_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s007020050015","volume":"107","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2000","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Molina JA, de Bustos F, Garc\u00eda-Redondo A, G\u00f3mez-Escalonilla C, Mart\u00ednez-Salio A, et al. Serum levels of coenzyme Q10 in patients with Parkinson\u2019s disease. J Neural Transm. 2000;107:177\u201381.","journal-title":"J Neural Transm."},{"key":"124_CR27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2012.03.023","volume":"318","author":"LK Mischley","year":"2012","unstructured":"Mischley LK, Allen J, Bradley R. Coenzyme Q10 deficiency in patients with Parkinson\u2019s disease. J Neurol Sci. 2012;318:72\u20135.","journal-title":"J Neurol Sci."},{"key":"124_CR28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10545-011-9433-2","volume":"35","author":"O Braissant","year":"2012","unstructured":"Braissant O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. J Inherit Metab Dis. 2012;35:655\u201364.","journal-title":"J Inherit Metab Dis."},{"key":"124_CR29","doi-asserted-by":"crossref","first-page":"21295","DOI":"10.1074\/jbc.M501527200","volume":"280","author":"AM James","year":"2005","unstructured":"James AM, Cochem\u00e9 HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280:21295\u2013312.","journal-title":"J Biol Chem."},{"key":"124_CR30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/abbi.1996.0267","volume":"330","author":"MD Esposti","year":"1996","unstructured":"Esposti MD, Ngo A, Ghelli A, Benelli B, Carelli V, McLennan H, et al. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996;330:395\u2013400.","journal-title":"Arch Biochem Biophys."},{"key":"124_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12640-011-9245-z","volume":"20","author":"KK Tai","year":"2011","unstructured":"Tai KK, Pham L, Truong DD. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res. 2011;20:321\u20138.","journal-title":"Neurotox Res."},{"key":"124_CR32","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","volume":"80","author":"B Borowsky","year":"2013","unstructured":"Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 2013;80:1934\u201341.","journal-title":"Neurology."},{"key":"124_CR33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tips.2004.03.003","volume":"25","author":"W Meissner","year":"2004","unstructured":"Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson\u2019s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci. 2004;25:249\u201353.","journal-title":"Trends Pharmacol Sci."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0124-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0124-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:39:53Z","timestamp":1596836393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0124-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0124-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,16]]}}}